Specific Effects of Escitalopram on Neuroendocrine Response
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00150527 |
Recruitment Status
:
Completed
First Posted
: September 8, 2005
Last Update Posted
: February 5, 2009
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Healthy | Drug: Citalopram Drug: Escitalopram Drug: Dexamethasone Behavioral: Cold Pressor Test |
Study Type : | Observational |
Actual Enrollment : | 8 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Specific Effects of Escitalopram on Neuroendocrine Response |
Study Start Date : | September 2005 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | December 2007 |
-
Drug: Citalopram
- The effect of the drugs on serum cortisol and ACTH following a single dose of each drug. [ Time Frame: 4hrs ]
- Side effects following a single dose of the drug [ Time Frame: 4hrs ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 59 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- The age range will be restricted to between 18 and 59 years of age.
- Subjects must be fit and have no history of significant illness.
- Subjects must have no risk factors for HIV or viral hepatitis.
- Subjects must be non-smokers, free of medication, and consume alcoholic and caffeinated beverages in moderation.
- Subjects must also be in good psychological health with no history of psychiatric illness.
Exclusion Criteria:
- Personal history of psychiatric illness, habitual smoking, illicit or prescription drug use, high intake of alcohol (>10 drinks/week) or caffeine (>500 mg caffeine/day), shift work, pregnancy, personal or familial history of seizures, significant medical illness or treatment in the last six months, significant physical or laboratory abnormalities, or current use of a weight loss diet.
- Women entering the study must be on a reliable form of birth control, i.e., tubal ligation, hysterectomy, oral contraceptives, abstinence, or vasectomy in partner.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00150527
Canada, Ontario | |
Providence Centre, Mental Health Services | |
Kingston, Ontario, Canada, K7L 4X3 |
Principal Investigator: | Nicholas J Delva, MD | Queen's University |
Responsible Party: | Dr. Nicholas Delva, Dalhousie University |
ClinicalTrials.gov Identifier: | NCT00150527 History of Changes |
Other Study ID Numbers: |
ESCIT001 |
First Posted: | September 8, 2005 Key Record Dates |
Last Update Posted: | February 5, 2009 |
Last Verified: | February 2009 |
Keywords provided by Queen's University:
antidepressive agents |
Additional relevant MeSH terms:
Dexamethasone Dexetimide Citalopram Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Serotonin Uptake Inhibitors |
Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Antiparkinson Agents Anti-Dyskinesia Agents Parasympatholytics Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents |